Translational CLL research to develop new standards of clinical care
Our research is focused on identifying new pathways with relevance for the pathogenesis of CLL. To pursue this aim, we employ in vitro biochemical assays, as well as genetically engineered mouse models. We further aim to develop novel, targeted therapies for CLL patients with the aim to achieve a non-toxic, long-term control of this leukemia entity. For that purpose, we perform early phase clinical trials, as well as large approval trials within the German CLL Study Group.
Department I of Internal Medicine
Center of Integrated Oncology ABCD
University Hospital of Cologne
Kerpener Str. 62
Tel. +49 221 478-39706
Find out more: